BIOA

BioAge Labs Inc

Oct 21 • 04:00PM ET

5.30

-0.06 -1.12 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Held by: VTI IWM VXF IWN SCHA VTWO FESM IWC VTWV RSSL

Index	RUT	P/E	-	EPS (ttm)	-2.24	Insider Own	41.29%	Shs Outstand	35.85M	Perf Week	-3.81%
Market Cap	190.01M	Forward P/E	-	EPS next Y	-2.51	Insider Trans	0.00%	Shs Float	21.05M	Perf Month	3.72%
Enterprise Value	-98.54M	PEG	-	EPS next Q	-0.58	Inst Own	33.98%	Short Float	11.84%	Perf Quarter	9.28%
Income	-79.03M	P/S	49.23	EPS this Y	66.86%	Inst Trans	2.83%	Short Ratio	15.02	Perf Half Y	26.19%
Sales	3.86M	P/B	0.64	EPS next Y	-14.07%	ROA	-32.48%	Short Interest	2.49M	Perf YTD	-8.46%
Book/sh	8.22	P/C	0.64	EPS next 5Y	26.87%	ROE	-35.88%	52W High	26.62 -80.09%	Perf Year	-76.95%
Cash/sh	8.29	P/FCF	-	EPS past 3/5Y	-30.62% -	ROIC	-26.58%	52W Low	2.88 84.03%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	95.34%	Volatility	6.23% 5.41%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-25.53	EPS Y/Y TTM	-	Oper. Margin	-2364.20%	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.21	Sales Y/Y TTM	-	Profit Margin	-2045.74%	RSI (14)	49.59	Recom	3.50
Dividend Gr. 3/5Y	- -	Current Ratio	13.21	EPS Q/Q	-51.32%	SMA20	-3.69%	Beta	1.82	Target Price	4.67
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	4.94%	Rel Volume	2.28	Prev Close	5.36
Employees	64	LT Debt/Eq	0.01	Earnings	Aug 06 AMC	SMA200	17.24%	Avg Volume	166.00K	Price	5.30
IPO	Sep 26, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-24.56% -	Trades		Volume	368,293	Change	-1.12%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight	$40 → $5
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$42 → $7
Dec-09-24	Downgrade	Citigroup	Buy → Neutral	$45 → $7
Oct-21-24	Initiated	Morgan Stanley	Overweight	$40
Oct-21-24	Initiated	Jefferies	Buy	$42
Oct-21-24	Initiated	Citigroup	Buy	$45

Aug-20-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 07:36AM	BioAge commences dosing in trial of obesity treatment candidate BGE-102 (Clinical Trials Arena)
Aug-15-25 09:00AM	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Aug-06-25 04:30PM	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-29-25 10:23AM	BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery (Insider Monkey)
06:00PM	Loading…
Jun-21-25 06:00PM	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions (GlobeNewswire)
Jun-17-25 09:00AM	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank (GlobeNewswire)
Jun-03-25 09:00AM	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates (GlobeNewswire)
May-30-25 09:05AM	BioAge Labs completes IND-enabling studies for BGE-102 (TipRanks)
May-29-25 11:18PM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)
09:00AM	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic (GlobeNewswire)
May-27-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
May-06-25 04:30PM	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-21-25 01:02PM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Mar-22-25 11:00AM	Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings (SeekingAlpha)
04:30PM	Loading…
Mar-20-25 04:30PM	BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 (GlobeNewswire)
Mar-17-25 01:54PM	BioArctic receives Orphan Drug Designation for exidavnemab the US (PR Newswire)
Mar-04-25 05:07AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-20-25 04:30PM	BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
10:36AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-16-25 07:18AM	BIOA COURT NEWS: BioAge Labs has been Sued for Securities Violations; Contact BFA Law by March 10 if You Lost Money (NASDAQ:BIOA) (GlobeNewswire)
Feb-14-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire) +5.97%
Feb-13-25 08:42AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Feb-07-25 05:45AM	BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-30-25 09:01AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive) -6.40%
Jan-28-25 07:27PM	Kessler Topaz Meltzer & Check, LLP Encourages BioAge Labs, Inc. Investors with Losses to Contact the Firm (PR Newswire)
09:00AM	BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs (GlobeNewswire)
Jan-24-25 05:45AM	Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-22-25 03:00AM	After an obesity stumble, BioAge reconnects with its longevity pipeline (Pharma Voice)
05:45AM	Loading…
Jan-21-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-18-25 03:07AM	BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10 (Newsfile)
Jan-06-25 09:00PM	Bragar Eagel and Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm (GlobeNewswire) -7.39%
Jan-03-25 12:51PM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (PR Newswire)
Jan-02-25 09:35AM	BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-01-25 05:00AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-27-24 11:32AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -6.46%
09:18AM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Dec-26-24 07:23AM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA) (Newsfile)
Dec-25-24 07:04AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-23-24 10:19AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-19-24 01:15PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) +20.23%
05:46AM	BioAge and Novartis seek drug targets for ageing-related diseases (Pharmaceutical Technology)
Dec-18-24 09:00AM	BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions (GlobeNewswire)
Dec-16-24 04:20PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-13-24 10:31AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile) -6.75%
Dec-12-24 06:34PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-09-24 07:51PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -76.85%
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
Dec-07-24 06:34AM	BioAge shares tumble after decision to halt obesity drug study (BioPharma Dive)
Dec-06-24 04:35PM	BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity (GlobeNewswire) +9.36% -76.85%
Dec-05-24 04:30PM	BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic (GlobeNewswire)
Dec-04-24 04:47PM	Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Nov-21-24 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 11:01PM	BioAge Labs Reports Strong Q3 2024 Achievements (TipRanks) -11.78%
Nov-07-24 04:30PM	BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM	BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 (GlobeNewswire)
Oct-24-24 09:00AM	BioAge Labs to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 10:53AM	Wall Street analysts initiate coverage of BioAge Labs (Investing.com) +8.26%
Oct-17-24 09:45AM	Prediction: These 2 Stocks Could Soar in 2025 (Motley Fool)
Oct-12-24 02:31PM	Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock (Motley Fool)
Oct-07-24 09:10PM	RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc (GuruFocus.com)
Oct-05-24 07:15AM	3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October (Motley Fool)
Oct-03-24 09:05AM	This IPO Biotech Stock Could Be the Next Eli Lilly (Motley Fool) +5.73%
Oct-01-24 04:30PM	BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement (GlobeNewswire)
Sep-26-24 04:08PM	BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO (Investor's Business Daily)
02:36PM	A weight loss drug developer's stock soars after a $198 million IPO (Quartz)
08:25AM	BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq (FastCompany)
Sep-25-24 08:00PM	BioAge Labs Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
04:13PM	BioAge prices $198M IPO, validating pivot to obesity drug research (BioPharma Dive)
11:27AM	A weight loss drug maker is aiming for a big IPO (Quartz)
Jan-01-01 12:00AM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIOA

BioAge Labs Inc

Upgrade your FINVIZ experience